Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE UCCD phase 2b dose-ranging study of TEV-48574 in ulcerative colitis and Crohn's disease
2021-006881-19Phase 2Active
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of duvakitug in autoimmune colitis, Crohn's disease and inflammatory bowel disease (IBD) (6 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Week 14 response and Dose response characterization. Started Oct 2022; status: active.
02
Drugs
duvakitug
03
Conditions
autoimmune colitisCrohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2021-006881-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006881-19.